Osimertinib Tops Standard EGFR-TKI for EGFR+ NSCLC

This article originally appeared here.
Share this content:
Osimertinib Tops Standard EGFR-TKI for <i>EGFR</i>&#43; NSCLC
Osimertinib Tops Standard EGFR-TKI for EGFR+ NSCLC

MONDAY, Nov. 20, 2017 (HealthDay News) -- For patients with previously untreated, epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC), treatment with osimertinib is associated with longer progression-free survival than a standard EGFR tyrosine kinase inhibitor (TKI), according to a study published online Nov. 18 in the New England Journal of Medicine to coincide with the European Society for Medical Oncology Asia 2017 Congress, held from Nov. 17 to 19 in Singapore.

Jean-Charles Soria, M.D., Ph.D., from the Gustave Roussy Cancer Campus and University Paris-Sud, and colleagues conducted a phase 3 trial involving 556 patients with previously untreated EGFR mutation-positive advanced NSCLC. Participants were randomized to receive osimertinib or standard EGFR-TKI.

The researchers found that median progression-free survival was significantly longer with osimertinib than EGFR-TKIs (18.9 versus 10.2 months; hazard ratio for disease progression or death, 0.46 [95 percent confidence interval, 0.37 to 0.57; P < 0.001]). The two groups had a similar objective response rate (80 and 76 percent, respectively; odds ratio, 1.27 [95 percent confidence interval, 0.85 to 1.90; P = 0.24]). The median response duration was 17.2 months with osimertinib and 8.5 months with standard EGFR-TKIs. Grade 3 or higher adverse events were less frequent with osimertinib (34 versus 45 percent).

"Osimertinib showed efficacy superior to that of standard EGFR-TKIs in the first-line treatment of EGFR mutation-positive advanced NSCLC, with a similar safety profile and lower rates of serious adverse events," the authors write.

The study was funded by AstraZeneca, the manufacturer of osimertinib.

Abstract
Full Text
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Compression Collar May Protect Brain of Female Soccer Players

Compression Collar May Protect Brain of Female Soccer ...

No white matter changes among female high school soccer athletes who wore compression collar

Fertility Rates Down for Each Urbanization Level 2007 to 2017

Fertility Rates Down for Each Urbanization Level 2007 ...

Fertility rates decreased from 2007 to 2017 with larger decreases in metro versus rural counties

Lung Cancer Deaths 28 Lower in California Than Rest of U.S.

Lung Cancer Deaths 28&#37; Lower in California Than ...

Among those aged 18 to 35, California has had larger drops in smoking initiation, intensity, more quitting

is free, fast, and customized just for you!




Already a member?

Sign In Now »